Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended		115 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011
Revenues
OTC product revenue					$ 25,648
Medical device revenue					14,109
Total revenues					39,757
Cost of sales					15,216
Gross profit					24,541
Operating expenses
Research and development	2,007,368	2,130,349	3,529,472	2,923,283	32,814,970
General and administrative	3,203,814	3,223,699	5,707,485	5,131,052	51,270,486
Amortization	167,780	167,780	335,560	335,560	5,782,817
Total operating loss	(5,378,962)	(5,521,828)	(9,572,517)	(8,389,895)	(89,843,732)
Gain on sale of fixed assets					55,075
Loss on extinguishment of debt					(825,867)
Investment income	213	268	369	318	650,712
Gain on change in fair value of warrant liability	843,271	2,137,746	32,176	1,502,747	2,171,821
Net interest expense					(8,098,004)
Net loss	(4,535,478)	(3,383,814)	(9,539,972)	(6,886,830)	(95,889,995)
Dividends on preferred stock	(64,224)	(2,244,392)	(134,158)	(10,216,635)
Net loss applicable to common shareholders	$ (4,599,702)	$ (5,628,206)	$ (9,674,130)	$ (17,103,465)
Basic and diluted loss per common share	$ (0.04)	$ (0.07)	$ (0.09)	$ (0.23)
Weighted average number of common shares outstanding - basic and diluted	105,794,099	78,132,005	101,914,292	73,580,080